Internally standardized simultaneous assay of propafenone and 5-hydroxypropafenone enantiomers in human plasma by means of high performance liquid chromatography.
A high performance liquid chromatographic method with internal analog standardization for the quantification of propafenone and 5-hydroxypropafenone enantiomers in human plasma is described. The method comprises extraction from alkalinized plasma into a toluene/diethylether phase (9:1), separation of the optical antipodes on a silica gel column using N-tert-Boc-(L)-proline as the chiral additive to the mobile phase and UV detection. A detection limit of 10 pmol/assay was established for the propafenone enantiomers, whereas for the optical antipodes of 5-hydroxypropafenone the limit was around 50 pmol/assay. Under routine conditions the limit of quantification (variation coefficient 15%) for the propafenone enantiomers is about 13 pmol/assay and for the 5-hydroxypropafenone enantiomers it is 66 pmol/assay. The determination method for the enantiomers is not impaired by the other metabolites. The suitability of the method for human pharmacology studies is demonstrated with samples obtained from healthy subjects.
Kern
R
R
Knoll AG, Department of Biochemistry, Ludwigshafen/Rhine, Germany.
D000319:Adrenergic beta-Antagonists / Q000097:blood* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D011405:Propafenone / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D013056:Spectrophotometry, Ultraviolet; D013237:Stereoisomerism
D000319:Adrenergic beta-Antagonists; D011405:Propafenone; C044307:5-hydroxypropafenone